annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 52G Prognosis and prognostic factors of a large retrospective series of mucinous
borderline tumors of the ovary (excluding peritoneal pseudomyxoma).
(Abstract #5096)
C. Uzan, M. Koskas, S. Gouy, P. Pautier, C. Lhomme, C. Balleyguier,
C. Haie-Meder, P. Duvillard, P. Morice
Brd. 52H Sexual activity and functioning in women who underwent
salpingo-oophorectomy to prevent hereditary breast ovarian cancer.
(Abstract #5097)
T. M. Michelsen, A. A. Dahl, C. Trope, A. Dørum
Brd. 53A The efficacy and toxicity of belotecan (CKD-602) combined with platinum in
patients with recurrent epithelial ovarian cancer. (Abstract #5098)
Y. Kim, S. Lee, S. Kim, D. Kim, J. Kim, J. Nam, Y. T. Kim
Brd. 53B Proliferation and lymphangiogenesis markers, and risk of lymph-nodal
metastasis in early cervical cancer. (Abstract #5099)
S. Bogliolo, A. Buenerd, P. Mathevet, F. Lecuru
Brd. 53F Prognostic impact of primary surgical outcome on survival after recurrence
in patients with advanced ovarian cancer: Analysis of prospective
randomized phase III trials. (Abstract #5100)
S. Mahner, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, J. Pfisterer,
A. Du Bois
Brd. 53G Relationship between ERCC1 C8092A and Mad1 G558A polymorphism with
disease progression, and survival in patients with advanced epithelial
ovarian cancer treated with induction chemotherapy with carboplatine
paclitaxel (PC). (Abstract #5101)
L. H. Montalvo, F. M. Vasquez, D. G. Rincon, C. C. Hernandez, M. S. Andrade,
P. F. Martinez, C. D. Romero
Brd. 53H Interrelated bowel symptoms to fecal incontinence among gynecologic
cancer survivors. (Abstract #5102)
G. Dunberger
Brd. 54A Inactivation of O 6 -methyguanine-DNA methyltransferase (MGMT) by
promoter hyermethylation: A key factor of epithelial ovarian carcinogenesis
in specific histologic types. (Abstract #5103)
H. Roh, W. Joo, S. Lee, H. Yoo
Brd. 54B Neoadjuvant chemotherapy in second trimester pregnant patients with
cervical cancer: First study on in vivo concentrations of cisplatinum in fetal
and maternal compartments. (Abstract #5104)
S. Marnitz, A. H. Schmittel, K. Hasenbein, G. Favero, A. Schneider, C. Köhler
Brd. 54F Development of a nomogram to predict progression-free survival in patients
with platinum-sensitive recurrent ovarian cancer based on the CALYPSO
trial. (Abstract #5105)
C. K. Lee, E. Guardiola, T. Hogberg, M. Friedlander, J. Bentley, U. Denison,
I. B. Vergote, C. Pisano, G. Parma, P. Wimberger
Brd. 54G What do primary and recurrent ovarian cancer patients (OC) expect from
their doctors? Final results of a German survey in 608 patients. (Abstract
#5106)
G. Oskay-Özcelik, S. Neubert, K. Münstedt, C. Liebrich, L. C. Hanker, R. Lorenz,
P. Wimberger, S. Mahner, H. Hindenburg, J. Sehouli
Brd. 54H A phase I study of the infectivity enhanced CRAd Ad5-�24RGD for recurrent
gynecologic cancer. (Abstract #5107)
D. T. Curiel, M. Preuss, M. Wang, K. J. Kimball, M. N. Barnes, W. Wan, G. Siegal,
R. Harris, R. Aurigemma, R. D. Alvarez
Brd. 55A A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant
ovarian cancer: HOG GYN-111. (Abstract #5108)
D. Matei, R. Ramasubbaiah, J. Schilder, S. M. Perkins, C. Whalen, T. Breen,
C. S. Johnson, M. Callahan, T. Jones, G. Sutton
Brd. 55B Patterns of first recurrence following adjuvant intraperitoneal chemotherapy
for advanced ovarian cancer. (Abstract #5109)
E. J. Tanner, F. Dao, O. Zivanovic, S. M. Kehoe, D. R. Black, J. A. Konner,
R. R. Barakat, S. M. Lichtman, D. A. Levine
174